Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $2.02, $1.32 better than the analyst estimate of $0.70. Revenue for the quarter came in at $611.09 million versus the consensus estimate of $532.86 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Jefferies Downgrades Alfen (ALFEN:NA) (ALFNF) to Hold
- Etsy upgraded to buy at BofA on durable growth, buyback potential
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
